Review
doi: 10.3389/fmed.2018.00022.
eCollection 2018.
Hereditary Angioedema: The Economics of Treatment of an Orphan Disease
Affiliations
- PMID: 29503818
- PMCID: PMC5820358
- DOI: 10.3389/fmed.2018.00022
Item in Clipboard
Review
Hereditary Angioedema: The Economics of Treatment of an Orphan Disease
Front Med (Lausanne).
.
Abstract
This review will discuss the cost burden of hereditary angioedema on patients, healthcare systems, and society. The impact of availability of and access to novel and specific therapies on morbidity, mortality, and the overall burden of disease will be explored along with potential changes in treatment paradigms to improve effectiveness and reduce cost of treatment. The prevalence of orphan diseases, legislative incentives to encourage development of orphan disease therapies and the impact of orphan disease treatment on healthcare payment systems will be discussed.
Keywords: burden; health economics; hereditary angioedema; orphan disease; treatment.
Similar articles
-
Pharmacoeconomics of Orphan Disease Treatment with a Focus on Hereditary Angioedema.Immunol Allergy Clin North Am. 2017 Aug;37(3):617-628. doi: 10.1016/j.iac.2017.03.004. Epub 2017 May 13. Immunol Allergy Clin North Am. 2017. PMID: 28687113 Review.
-
Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?Orphanet J Rare Dis. 2017 Jan 5;12(1):1. doi: 10.1186/s13023-016-0551-7. Orphanet J Rare Dis. 2017. PMID: 28057032 Free PMC article.
-
An open-label study to evaluate the long-term safety and efficacy of lanadelumab for prevention of attacks in hereditary angioedema: design of the HELP study extension.Clin Transl Allergy. 2017 Oct 6;7:36. doi: 10.1186/s13601-017-0172-9. eCollection 2017. Clin Transl Allergy. 2017. PMID: 29043014 Free PMC article.
-
Generic Substitution of Orphan Drugs for the Treatment of Rare Diseases: Exploring the Potential Challenges.Drugs. 2018 Mar;78(4):399-410. doi: 10.1007/s40265-018-0882-x. Drugs. 2018. PMID: 29464665 Review.
-
FDA's Office of Orphan Products Development: providing incentives to promote the development of products for rare diseases.J Pharmacokinet Pharmacodyn. 2019 Oct;46(5):387-393. doi: 10.1007/s10928-019-09645-4. Epub 2019 Jul 5. J Pharmacokinet Pharmacodyn. 2019. PMID: 31278433
Cited by
-
Advances in drug allergy, urticaria, angioedema, and anaphylaxis in 2018.J Allergy Clin Immunol. 2019 Aug;144(2):381-392. doi: 10.1016/j.jaci.2019.06.010. Epub 2019 Jun 24. J Allergy Clin Immunol. 2019. PMID: 31247266 Free PMC article. Review.
-
Interventions for the long-term prevention of hereditary angioedema attacks.Cochrane Database Syst Rev. 2022 Nov 3;11(11):CD013403. doi: 10.1002/14651858.CD013403.pub2. Cochrane Database Syst Rev. 2022. PMID: 36326435 Free PMC article.
-
Effect of Fresh Frozen Plasma Infusion on Hospital Length of Stay for Patients With Hereditary Angioedema.J Health Econ Outcomes Res. 2025 Jul 9;12(2):1-10. doi: 10.36469/001c.141171. eCollection 2025. J Health Econ Outcomes Res. 2025. PMID: 40656551 Free PMC article.
-
Lanadelumab for the Prophylactic Treatment of Hereditary Angioedema with C1 Inhibitor Deficiency: A Review of Preclinical and Phase I Studies.BioDrugs. 2019 Feb;33(1):33-43. doi: 10.1007/s40259-018-0325-y. BioDrugs. 2019. PMID: 30539362 Free PMC article. Review.
-
Costs and effects of on-demand treatment of hereditary angioedema in Italy: a prospective cohort study of 167 patients.BMJ Open. 2018 Jul 30;8(7):e022291. doi: 10.1136/bmjopen-2018-022291. BMJ Open. 2018. PMID: 30061443 Free PMC article.
References
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
